Invitreo Biosciences Inc.

Invitreo Biosciences appears to be a legitimate early-stage biotech entity focused on regenerative medicine and wound care, potentially spun out of academic research. However, the submission is severely compromised by hyperbolic and demonstrably false claims (e.g., 'most people have used my product', 'audience reach: everyone'). The financial data provided ('all time marketcap: 500000') is ambiguous and suggests very early-stage maturity or a misunderstanding of metrics. While the field (regenerative medicine) has high utility and innovation potential, the lack of verifiable traction and the low quality of the submission data result in a low score, positioning it as a small, unproven project rather than an established business.